Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies

OBJECTIVE: To evaluate the dose-response relationship of 10, 20, and 40 mg ponesimod and long-term efficacy and safety of ponesimod 20 mg using an analysis of combined data from the phase 2 Core and Extension studies in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In the Cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedman, Mark S., Pozzilli, Carlo, Havrdova, Eva Kubala, Lemle, Alexandre, Burcklen, Michel, Larbalestier, Anna, Hennessy, Brian, Sidorenko, Tatiana, Vaclavkova, Andrea, Olsson, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484728/
https://www.ncbi.nlm.nih.gov/pubmed/35667837
http://dx.doi.org/10.1212/WNL.0000000000200606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484728/
https://www.ncbi.nlm.nih.gov/pubmed/35667837
http://dx.doi.org/10.1212/WNL.0000000000200606

Ejemplares similares